CSIMarket
 


Zogenix Inc   (ZGNX)
Other Ticker:  
 

Cumulative Zogenix Inc 's Working Capital Ratio for Trailing Twelve Months Period

ZGNX's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ZGNX Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Current Liabilities Growth 5.84 % -15.74 % -21.92 % -38.64 % -5.27 %
Y / Y Current Assets Growth -37.29 % -11.98 % -12.99 % 58.31 % 93.45 %
Working Capital Ratio for Trailing Twelve Months Period 5.27 6.07 5.95 5.79 4.76
Total Ranking # 1182 # 835 # 815 # 796 #
Seq. Current Liabilities Growth 24.57 % 13.1 % 18.47 % -36.59 % -0.83 %
Seq. Current Assets Growth -5.56 % -9.83 % -8.43 % -19.57 % 32.55 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2021
On the trailing twelve months basis Due to growth in Current Liabilities in the IV. Quarter to $98 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 5.27 below Zogenix Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 421 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Zogenix Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ZGNX
Working Capital Ratio ZGNX in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 422
Sector # 775
S&P 500 # 1669


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
10.07 5.36 1.25
(Sep 30 2018)   (March 31, 2014)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Vera Therapeutics Inc   14.45 
Calcimedica Inc   14.42 
Vanda Pharmaceuticals Inc   14.42 
Acasti Pharma Inc   14.40 
Actinium Pharmaceuticals Inc   14.39 
Cormedix Inc   14.36 
Xenetic Biosciences Inc   14.20 
Citius Pharmaceuticals Inc   14.12 
Oramed Pharmaceuticals Inc   14.05 
Cryoport inc   14.04 
Tonix Pharmaceuticals Holding Corp   14.03 
Enanta Pharmaceuticals Inc  14.03 
Morphic Holding inc   14.02 
Lianbio  13.94 
Vistagen Therapeutics Inc   13.90 
Alzamend Neuro Inc   13.86 
Akero Therapeutics Inc   13.69 
89bio Inc   13.69 
Igm Biosciences Inc   13.56 
Avadel Pharmaceuticals Plc  13.50 
Intra cellular Therapies Inc   13.23 
Unicycive Therapeutics Inc   13.22 
Tyme Technologies Inc.  13.16 
Rhythm Pharmaceuticals inc   13.01 
Rapt Therapeutics Inc   12.96 
Equillium Inc   12.96 
Aadi Bioscience Inc   12.88 
Syndax Pharmaceuticals Inc   12.83 
Immutep Limited  12.81 
Cogent Biosciences Inc   12.80 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com